Stockscreener 앱 받기
26.71
4.23%
-1.18
시장 영업 전:
26.58
-0.13
-0.49%
Tg Therapeutics Inc 주식(TGTX)의 최신 뉴스
TG Therapeutics Faces Regulatory and Legal Risks with AI Integration - AInvest
Navigating AI Risks: TG Therapeutics Faces Regulatory and Legal Challenges - TipRanks
TG Therapeutics Boosts Financial Strength with New Securities Filing - AInvest
TG Therapeutics Inc's Financial Performance and Strategic Positioning - AInvest
Willdan Group's Price Target Raised by Wedbush to $120, Up 41.18% - AInvest
Tg Therapeutics 2025 Q2 Earnings Net Income Surges 309.8% - AInvest
TG Therapeutics: Strategic Capital Flexibility Fuels Briumvi's Global Expansion and R&D Momentum - AInvest
TG THERAPEUTICS, INC. SEC 10-Q Report - TradingView
TG Therapeutics raises BRIUMVI 2025 revenue guidance to $575M while advancing subcutaneous pipeline - MSN
TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance - MSN
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line - MSN
TG Therapeutics, Inc. (NASDAQ:TGTX) Q2 2025 Earnings Call Transcript - Insider Monkey
TR | OpenAI4o Maintains TG Therapeutics(TGTX.US) With Hold Rating, Cuts Target Price to $30 - 富途牛牛
TGTX Stock Falls 14.1% Amid Market Volatility - AInvest
TGTX Raises FY25 Revenue Projection, BRIUMVI Target Increased - AInvest
TG Therapeutics’ Earnings Call Highlights BRIUMVI Success - TipRanks
TGTX Down As Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line - Barchart.com
New Lantern Expands AI Radiology Platform with Mammography and PET/CT Viewers - AInvest
TG Therapeutics (TGTX) Misses Q2 Earnings Estimates - MSN
TG Therapeutics Second Quarter 2025 Earnings: Misses Expectations - simplywall.st
TG Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... - Yahoo Finance
TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada
TG Therapeutics: Q2 Earnings Snapshot - Connecticut Post
TG Therapeutics Boosts Revenue Forecast Amid Strong BRIUMVI Sales - TipRanks
TG Therapeutics Stock Plunges 17.99% on Missed Earnings Despite Strong Revenue Surging Trading Volume Ranks 325th in Market Activity - AInvest
Update: TG Therapeutics Shares Fall After Q2 Earnings Miss Expectations - 富途牛牛
Investor Calendar Invites You to the TG Therapeutics, Inc First Quarter 2016 Earnings Conference Call and Webcast Live on Tuesday May 10, 2016 - ACCESS Newswire
This Top 3% Stock Raised Its Outlook. So, Why Did Shares Crash? - Investor's Business Daily
Health Care Stocks See Gains On Strong Results And Approvals - Finimize
TG Therapeutics stock falls despite in-line Briumvi sales as BofA reiterates Underperform - Investing.com India
TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug - Stocktwits
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results - Benzinga
TG Therapeutics Stock Tumbles 16% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug - MSN
Why Is TG Therapeutics Stock Falling Monday?TG Therapeutics (NASDAQ:TGTX) - Benzinga
TG Therapeutics Q2 Revenue Up 91% - The Motley Fool
TG Therapeutics Q2 Revenue Up 91% - Nasdaq
TG Therapeutics: Strong Market Position and Growth Prospects Make It an Attractive Buy - TipRanks
Why Top 3% Stock TG Therapeutics Crashed Despite Raising Its 2025 Outlook - MSN
TG Therapeutics falls after Q2 miss despite guidance raise - MSN
TG Therapeutics stock falls after Q2 miss (TGTX:NASDAQ) - Seeking Alpha
TG Therapeutics Q2 2025: Unpacking Contradictions in Market Share, Subcutaneous Trials, and Payer Demand Trends - AInvest
TG Therapeutics Plunges 15.76%—Is the Earnings Miss Just the Beginning? - AInvest
TG Therapeutics and BRIUMVI: A Deep Dive into Accelerating Revenue and Strategic Expansion in the MS Market - AInvest
Earnings call transcript: TG Therapeutics Q2 2025 misses EPS, raises revenue - Investing.com UK
TG Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
TG Therapeutics Raises Outlook As BRIUMVI Sales Climb - Finimize
TG Therapeutics Reports Q2 Profit, Misses Wall Street ExpectationsNews and Statistics - IndexBox
TG Therapeutics reports Q2 EPS 17c, consensus 29c - TipRanks
TG Therapeutics Reports Second Quarter 2025 Financial Results - TradingView
TG Therapeutics' Q2 Surge and Strategic Moves: A Compelling Case for BRIUMVI-Driven Growth and Shareholder Value - AInvest
TG Therapeutics' Q2 2025 Earnings Outlook: A Strategic Catalyst for Investors - AInvest
TG Therapeutics Q2 Earnings, Revenue Rise - MarketScreener
0.24%
3.39%
자본화:
|
볼륨(24시간):